Skip to main content
Signal8

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

$BLRXPress releaseNov 16, 2026, 7:00 AM ETRead the release

BioLineRx and Hemispherian presented two posters on GLIX1, a first-in-class oral TET2 activator, at the 31st Society for Neuro-Oncology Annual Meeting. The Phase 1/2a study in high-grade glioma has initiated its fourth cohort with no significant treatment-emergent adverse events, and remaining cohorts will add a window-of-opportunity setting to directly assess brain penetration in human tumor tissue. Preclinical data showed robust, dose-dependent antitumor activity across multiple GBM models, including tumor eradication in the SNB19 model and growth inhibition in a TMZ-resistant PDX where TMZ failed, with confirmed brain penetration and dose-dependent 5hmC increases.

Key figures

Drug Name
GLIX1
Phase Of Trial
Phase 1/2a
Data timing
study results expected first half of 2027
Cohort status
fourth cohort dosing initiated
Trial identifier
NCT07464925

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.